Icure Pharm Overview

  • Founded
  • 2000
  • Status
  • Public
  • Employees
  • 249
  • Stock Symbol
  • 175250
Stock Symbol
  • Share Price
  • $34.32
  • (As of Monday Closing)

Icure Pharm General Information


Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Stock Exchange
Primary Office
  • 10 Bongeunsa-Ro 104-Gil, Gangnam-Gu
  • Seoul, Seocho-gu 06170
  • South Korea
+82 00-0000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Icure Pharm Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$34.32 $34.74 $28.61 - $62.36 $322M 9.4M 241K -$3.05

Icure Pharm Financials Summary

In Thousands,
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 347,358 472,059 240,870 151,952
Revenue 62,185 76,348 52,246 30,316
EBITDA (17,076) (1,940) (3,088) (6,171)
Net Income (26,395) (10,684) (7,504) (7,174)
Total Assets 187,544 178,885 182,931 105,965
Total Debt 65,321 53,897 72,913 18,769
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Icure Pharm Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Icure Pharm‘s full profile, request access.

Request a free trial

Icure Pharm Patents

Icure Pharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2020158514-A Cataplasm agent containing ultraviolet-curable hydrogel for transdermal administration Granted 11-Feb-2016 000000000
JP-6909520-B2 Cataplasma containing uv curable hydrogel for transdermal administration Active 11-Feb-2016 000000000
JP-2019507142-A Ultraviolet curable hydrogel resin for transdermal administration, hydrogel, and cataplasma agent containing the same Granted 11-Feb-2016 000000000 0
JP-6755957-B2 Ultraviolet curable hydrogel resin for transdermal administration, hydrogel and cataplasma containing it Active 11-Feb-2016 000000000
EP-3415141-A4 Ultraviolet-hardening hydrogel resin and hydrogel for transdermal administration, and cataplasm agent containing same Pending 11-Feb-2016 A61K9/703 0

Icure Pharm Executive Team (2)

Name Title Board Seat Contact Info
YoungKweon Choi Ph.D Founder & Chief Executive Officer
You’re viewing 1 of 2 executive team members. Get the full list »

Icure Pharm Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial